Soligenix’s dusquetide granted FDA IND clearance for Phase 2 trial in Behcet’s

Soligenix announced that the FDA has cleared the Investigational New Drug – IND – application for a Phase 2a clinical trial designed to evaluate the safety and efficacy of SGX945 – dusquetide – in the treatment of aphthous ulcers in Behcet’s Disease and expected to begin patient enrollment in the second half of 2024. Efficacy endpoints will include the extent of lesion clearance, timeline to lesion clearance, and patient reported quality of life indices.